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Doccurred largely in those who underwent aortic root
replacement and had preoperative AI caused by congenital
aortic valve disease. Thus it is possible that the operative
technique plays a role on late dilation and eventual failure
of the pulmonary autograft, but our sample size was rela-
tively small to demonstrate that.
In addition to the complexity of theRoss operation, another
common criticism is that it requires a pulmonary homograft,
which can also fail. Failure of the pulmonary homograft is
a problem in young children but less so in young adults and
older patients.16-18 Actually, the pulmonary homograft in
young children seems to be more durable after the Ross oper-
ation than after other types of right ventricular outflow tract
reconstruction for congenital heart disease.18 In our series
only 3 patients have required reintervention for a freedom
from reoperation of 97.3%  1.6%, but the freedom from
pulmonary dysfunction, as defined as moderate or severe
pulmonary insufficiency, a peak systolic gradient of 40 mm
Hg or greater, or both at 15 years, was 70.8%  6.8%. The
fate of the pulmonary homograft after the Ross operation
varies among reports depending on how dysfunction is
defined, but it is not a serious problem.10-12 In addition,
with the advent of catheter-based pulmonary valve implanta-
tion, this problem is further mitigated.
In spite of all the valve-related problems described in the
study, 185 (87%) of 212 patients were free from any cardio-
vascular complications after a mean follow-up of 10 years. If
patients with a dilated aortic annulus were excluded, the
results were indeed excellent and probably compare favor-
ably with those of other types of heart valve substitutes for
aortic valve replacement in young adults.18-20
In summary, this study showed excellent long-term out-
comes after the Ross operation in female patients and in
other patients with an aortic annulus less than 27 mm in di-
ameter. Patients with aortic stenosis are more likely to do
well than those with AI. The technique of implantation
had no demonstrable effect on the fate of the operation,
but patients with a dilated aortic annulus did not fare well,
and reduction of the aortic annulus at the time of surgical
intervention did not resolve the problem, suggesting that
a dilated aortic annulus might be a marker for premature
degeneration of the pulmonary autograft cusps.References
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Dr Lawrence Cohn (Boston, Mass). Tirone, as usual, an excel-
lent paper with superb results. I have no conflicts to present. I think
especially notable is the superb survival, as it should be in this very
young group of adults. I think the real message is that proper pa-
tients should have excellent and good early and late survival; the
gender observation is obviously quite new.
The message I got from your paper is that you should not do
a Ross operation if you have severe aortic regurgitation with a bi-
cuspid aortic valve or when the aortic annulus is quite a bit bigger
than the pulmonary valve annulus. That seems very, very clear.
You did annular and sinotubular banding procedures. I am con-
cluding that they were not effective. Is that fair to say?
Dr David. That’s correct. I do believe that a dilated aortic annu-
lus is a marker of premature degenerative disease of a pulmonary
valve; work that we have been doing for 20 years now.
Dr Cohn. Agreed. Would it be fair then to say that aortic regur-
gitation in a bicuspid aortic valve is a contraindication to the Ross
operation?ardiovascular Surgery c Volume 139, Number 1 73
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DDr David. I no longer do the Ross procedure on these patients
because surgical adjustment of the dilated annulus did not prevent
the pulmonary cusps to degenerate prematurely.
DrCohn.Your reoperation rate for the pulmonary autograft was
very, very good. I found it fascinating that you did equally a number
of subcoronary procedures, as the original Ross procedure was con-
ceived, as opposed to the root. Are these intermingled? How do you
choose to do one or the other, or were these sequential? In all the
ones that we did, a much smaller series to be sure, but the only
ones I did were all root replacement.
Dr David.Our experience with aortic valve homograft preceded
the pulmonary autograft. I started doing aortic homografts when I
started practicing, and always opened the aortic root down to the
aortic annulus to increase exposure of the right and left aortic si-
nuses. If the relationship between the coronary artery orifices and
annulus was fairly normal, that is, the coronary artery was in the
center of the sinus, we scalloped the left and the right, did subcoro-
nary for the left and right, left the noncoronary sinus of the donor
valve was left intact, and did the upper anastomosis, closed the aor-
tic root at the end of the operation only if there was enough tissue. If
there was enough, we used a patch of autologous pericardium. So
there was a reason to do one or the other procedure. If the anatomy
was not normal, if the coronaries were at 180 degrees, it was diffi-
cult to align a tricuspid valve into it and those patients had root re-
placement. And that is the bias perhaps that cannot be measured. It
was an intraoperative decision to do one or the other procedure.
Dr Cohn. My last question relates to the reconstruction of the
pulmonary homograft. In our smaller series we found several pa-
tients that ended up with pulmonary trunk hyperplasia, endothelial
hyperplasia. Have you seen this in any of the patients, because you
had a moderate number that had pulmonary insufficiency and/or
pulmonary gradients greater than 40? As you said, you readjusted
those numbers from the abstract. Have you seen this and how do
you treat these people and when do you feel it is time to intervene
when you have this sort of progressive pulmonary stenosis or pul-
monary regurgitation?
Dr David. Every patient who had a mean systolic gradient by
echo more than 40 was a potential candidate to have pulmonary
valve intervention. Those patients underwent heart catheteriza-
tion, and it was amazing how often the echo gradients were in-
correct and at catheterization we found only mean gradients of
10 to 20 and, because the patients had no right ventricular hyper-
trophy of dysfunction, we left them alone. The stenosis almost
invariably is at the pulmonary artery level, not at the cusps.
The cusps remain pretty normal and the pulmonary artery of
the donor becomes stenotic. If it is possible that is caused by in-
flammatory reaction. Since it could be due inflammation, we
treated these patients with a high dose of aspirin, but aspirin is
the only thing we give. I don’t know if that inflammatory reaction
can be prevented. With advent of percutaneous valve deploy-
ment, managing pulmonary homograft dysfunction should
become less of problematic in the future.
Dr Cohn. Super paper.
Dr David. Thank you.
Dr Peter Skillington (Melbourne, Australia). Thank you very
much, Tirone. It was a very good paper. I just wonder what your
current approach is now then for a patient with coronary arteries ab-
normally positioned? Is it a subcoronary?74 The Journal of Thoracic and Cardiovascular SurgeDr David. Scalloped on the left and right, and then we leave the
noncoronary sinus of the pulmonary autograft intact, do a distal
anastomosis, unclamp, and then after you do the echo, if there is
enough tissue, close the root primarily around the modified sub-
coronary. If there is not enough tissue, we put a patch of pericar-
dium there to close.
Our intention was to prove that root replacement was bad. Our
data doesn’t support that.
Dr Skillington. You are not the first one to note that female pa-
tients seem to do better. Can you speculate as to the reasons for
that?
Dr David. I initially thought because most of them have aortic
stenosis as opposed to insufficiency. I don’t know enough about
the multivariable analysis but our biostatistician reran 3 or 4 times
different models, and women always emerged as a predictor of bet-
ter outcome. I don’t know the answer. As you said, we are not the
first ones to point this out. Ronald Elkins with a much larger series
showed that female was a protecting effect as well, and Dr Elkins
had done mostly root replacement.
Dr Skillington.My final question, what do you think the really
long-term fate of the pulmonary allograft valve is going to be?
Dr David. I think it is like the aortic homograft and is going to
fail, unfortunately. However, if at 20 years half of them are still
functioning well and they can deploy a percutaneous valve that
might last another 15, 20 years, it is not that big a deal. Obviously,
we had to adapt your practice to our environment. Where I practice,
anticoagulation on a 25-year-old is a major problem. It is not a mi-
nor thing for either young men or women to have a mechanical
valve and take Coumadin. So we continue seeking for a better bi-
ological valve. I don’t think the Ross is a bad option, and I have
to tell you that, since we discovered this last year, we have done an-
other 20 patients. We are doing a Ross routinely again for anyone
with aortic stenosis who does not wish to take anticoagulants. And,
of course, one has to be relatively young. It doesn’t make any sense
to do it in a 70-year-old, but in a 50-year-old or younger, why not?
Dr A. Sampath Kumar (New Delhi, India). Dr David, I must
congratulate you on awonderful experience and a good presentation
on this large series. We started doing Ross procedures in 1993, and
from the very first case we did only root replacements.We never did
a scalloped subcoronary. And we did not do a Ross procedure if the
aortic root annulus measured more than 30 mm. I think your obser-
vation is very correct and I agree with you that if there is aortic root
dilatation, we believe 30 mm is the limit. Beyond that, the Ross pro-
cedure is going to fail. The other observationwemade in rheumatics
is that the pulmonary valve is already subjected to high pressure be-
cause of the pulmonary hypertension and is a much better autograft
to use as a replacement for the aortic valve.
Thank you very much for giving me this opportunity to com-
ment.
DrDavid.A retrospective review from the tissue bank in Europe
supports what you are saying. There was a time in the early 1990s
that we would use a pulmonary homograft to replace the aortic
valve, and early failures were common. At five years, more than
half of them failed. At 10 years, approximately 1 in 3 was still func-
tioning as well as aortic valve homograft. They went back to the do-
nors, and the valves of donors with pulmonary hypertension did as
well as aortic homograft. They probably had had heart-lung trans-
plant, and the pulmonary valves of those donors tolerated systemicry c January 2010
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Dpressure much better, suggesting that the pulmonary valve might
adapt to high pressure. So the rheumatic who has pulmonary hyper-
tension is likely to do better because the pulmonary valve is indeed
already prepared to sustain systemic pressure.
DrKumar. There are several advantages with pulmonary hyper-
tension. First, the autograft is easier to take out because the muscle
is quite thick and you are not likely to injure the first septal artery.
The pulmonary artery wall is pretty thick, so it is very good; it has
already adapted to the high pressures in the aortic position. So I
think it is a good advantage to do it in patients with pulmonary
hypertension. Thank you.
Dr John Fehrenbacher (Indianapolis, Ind). I do have a disclo-
sure with CryoLife. I am a consultant.
Dr David, remarkable results. I don’t know in the literature that
any other mechanical or tissue valve has almost a 97% 15-year sur-
vival, but maybe in your hands, mechanical or tissue valves do.
Knowing these results, why not use the Ross in somebody who
has aortic insufficiency when it provides such excellent 15-year
survival versus putting in a mechanical or a tissue valve that may
not have these excellent results?
Dr David.Well, what I didn’t say was that all patients who had
reoperations did not die. So the most serious valve-related compli-
cation in this series, which was valve failure, was not a cause of
death and this may have contributed to a late survival similar toThe Journal of Thoracic and Cthat of a matched general population. Thus, if no patient died
from a valve-related complication, one should expect death only
by the same causes and in the population in general.
The problems of aortic insufficiency are more complicated. In
20-year-old patients who have a 30%-40% chance to have aortic
insufficiency at 15 years, I am not so sure the Ross is much better
than a tissue valve, particularly the newer tissue valves. So the
Ross procedure should give the patient results better than existing
bioprosthetic valves. Bioprosthetic valves are not bad anymore.
Some of them are actually very good. We have experience
with 2 of them: Carpentier-Edwards Perimount and Hancock II.
We practically have no reoperation for valve failure during the
first decade. In the second decade they come back but I think
it parallels the failures of the Ross for aortic insufficiency, but
not for aortic stenosis. So I think the Ross is an ideal procedure
for a stenotic aortic valve. It is less than perfect for aortic
insufficiency.
My main concern is that aortic insufficiency in congenital aortic
valve disease may be a marker for premature degenerative process
in a pulmonary valve. We published a study suggesting that bicus-
pid aortic valve was the bad fellow. I think we were wrong. It was
not bicuspid aortic valve; it was the bicuspid aortic valve with di-
lated aortic annulus that was bad. This does not apply to rheumatic
aortic insufficiency, as Professor Kumar mentioned.ardiovascular Surgery c Volume 139, Number 1 75
